Related Experiment Video
Updated: Jul 9, 2025
Mouse Kidney Transplantation: Models of Allograft Rejection
Published on: October 11, 2014
Targeted changes in blood lipids improves fibrosis in renal allografts
Yang-He Zhang1, Bin Liu2, Qingfei Meng1
1Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, 130021, China.
Background:
Chronic interstitial fibrosis is the primary barrier against the long-term survival of transplanted kidneys. Extending the lifespan of allografts is vital for ensuring the long-term health of patients undergoing kidney transplants. However, few targets and their clinical applications have been identified. Moreover, whether dyslipidemia facilitates fibrosis in renal allograft remains unclear.
Methods:
Blood samples were collected from patients who underwent kidney transplantation. Correlation analyses were conducted between the Banff score and body mass index, and serum levels of triacylglycerol, total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol. A rat model of renal transplantation was treated with the lipid-lowering drug, fenofibrate, and kidney fibrosis levels were determined by histochemical staining. Targeted metabolomic detection was conducted in blood samples from patients who underwent kidney transplantation and were divided into fibrotic and non-fibrotic groups. Rats undergoing renal transplantation were fed either an n-3 or n-6 polyunsaturated fatty acid (PUFA)-enriched diet. Immunohistochemical and Masson's trichrome staining were used to determine the degree of fibrosis.
Results:
Hyperlipidemia was associated with fibrosis development. Treatment with fenofibrate contributed to improve fibrosis in a rat model of renal transplantation. Moreover, n-3 PUFAs from fibrotic group showed significant downregulation compared to patients without fibrotic renal allografts, and n-3 PUFAs-enriched diet contributed to delayed fibrosis in a rat model of renal transplantation.
Conclusions:
This study suggests that hyperlipidemia facilitates fibrosis of renal allografts. Importantly, a new therapeutic approach was provided that may delay chronic interstitial fibrosis in transplanted kidneys by augmenting the n-3 PUFA content in the diet.
Insights
Hyperlipidemia accelerates kidney transplant fibrosis. Increasing dietary omega-3 fatty acids (n-3 PUFAs) may help delay this fibrosis, offering a new therapeutic strategy for transplant recipients.
Area of Science:
- Nephrology
- Transplantation Immunology
- Metabolic Disorders
Background:
- Chronic interstitial fibrosis limits long-term kidney allograft survival.
- Dyslipidemia's role in renal allograft fibrosis is not well understood.
- Identifying novel targets is crucial for improving transplant outcomes.
Purpose of the Study:
- To investigate the association between dyslipidemia and renal allograft fibrosis.
- To explore the potential of lipid-lowering agents and dietary fatty acids in mitigating fibrosis.
- To identify novel therapeutic strategies for preventing chronic interstitial fibrosis in transplanted kidneys.
Main Methods:
- Correlation analysis of lipid profiles and Banff scores in kidney transplant recipients.
- Evaluation of fenofibrate treatment in a rat renal transplantation model.
- Metabolomic profiling of fibrotic vs. non-fibrotic allografts.
- Assessment of n-3 and n-6 polyunsaturated fatty acid (PUFA) diets in a rat model.
Main Results:
- Hyperlipidemia correlated significantly with renal allograft fibrosis.
- Fenofibrate treatment improved fibrosis in a rat model.
- n-3 PUFAs were downregulated in fibrotic allografts, and an n-3 PUFA-enriched diet delayed fibrosis in rats.
Conclusions:
- Hyperlipidemia is a key facilitator of renal allograft fibrosis.
- Augmenting dietary n-3 PUFA content presents a promising therapeutic avenue to delay chronic interstitial fibrosis in transplanted kidneys.
